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Sale of Prescription Drugs Over the Internet
Abstract
Online drugstores represent one of the hottest categories in electronic commerce. The Internet offers gr
eat promise in expanding access to prescription drugs for the disabled, the elderly, and people living in
rural areas. But with this promise comes the danger of eliminating the safeguards that protect consumers
fr om inappropriate use of medications and adverse drug events. This Issue Brief highlights two studies
that investigate the availability of prescription drugs over the Internet, and focuses on the alarming ease
with which consumers can obtain drugs without seeing a physician or a pharmacist.
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Editor’s Note: Online drugstores represent one of the hottest categories in electronic
commerce. The Internet offers gr eat pr omise in expanding access to prescription
drugs for the disabled, the elderly, and people living in rural ar eas. But with this
promise comes the danger of eliminating the safeguar ds that pr otect consumers
fr om inappropriate use of medications and adv erse dr ug events. This Issue Brief
highlights two studies that investigate the av ailability of pr escription drugs over the
Internet, and focuses on the alarming ease with which consumers can obtain dr ugs
without seeing a physician or a pharmacist.

Selling prescription drugs
over the Internet can bypass
traditional regulations

Prescription drugs are well-r egulated in this country, by a system that includes
premar ket appr oval by the federal F ood & Drug Administration (FDA), state
licensure of health car e practitioners who ar e allowed to prescribe, and state o versight
of pharmacists and pharmacies that ar e allowed to dispense. The sale of prescription
drugs over the I nternet has challenged this r egulator y system because:
• Web sites based outside of the U.S. can easily market non-FDA-appr oved drugs
to consumers in this country.
• Health car e practitioners licensed in one state can easily pr escribe dr ugs to
patients they hav e never met in any state thr ough the Internet. However, under
existing law in most states, this is considered the unlicensed practice of medicine.
• Web-based pharmacies in one state can dispense pr escription drugs to consumers
in any state, ther eby bypassing each state’s regulations.

Study finds Web sites
selling prescription drugs
without physician visits or
prescriptions

Between Febr uar y and Mar ch 1999, Bloom and Iannacone catalogued Web sites
offering physician consultations and selling prescription drugs directly to the public.
They determined the r equirements for obtaining a pr escription, the availability of
online physician consultations, the geographic location of the company providing
the Web site, and the medications available for sale.
• Using multiple search engines, Bloom found 46Web sites that pr ovided prescription drugs, including 13 based outside the United States. Of these, all of the U.S.
sites and four international sites r equired a physician consultation or prescription
fr om the site’s consulting physician or a personal physician.
• Only five sites would reveal their geographic location (city and countr y) beyond
any information offer ed on the Internet. No site would reveal the specific addr ess
or qualifications of consulting physicians.
• U.S.-based Web sites primarily sold Viagra ®, used to treat impotence, and
Propecia ®, used to treat hair loss. Other sites also sold popular drugs used to treat
allergies, ar thritis, herpes, as well as dr ugs targeting weight-loss.

Viagra® is readily
available over the Internet

In April 1999, Armstr ong and colleagues investigated Web sites that sold Viagra ®
without a physician visit or prescription from an outside source. They chose Viagra ®
because of its potential consumer appeal and potential medical risks.
• Using various sear ch engines, Armstrong and colleagues found 86 sites selling
Viagra ® that did not r equire a physician visit or a pr escription from another
source. In the 10-day inter val betw een when they found the site and collected
data, nine of the sites ceased operating. Twenty-two of the sites appear ed to be
based outside of the U.S.
• Of the 77 r emaining sites, only 42 sites (55%) provided information about
contraindications, 34 (44%) about other potential adv erse effects, and 36 (47%)
about efficacy .
• Online medical evaluation, consisting of a medical history questionnaire, was
required by only 42 sites (55%), offered but not required by 4 sites (5%), and not
offer ed by 31 sites (40%). Only 35 sites (45%) asked about a pr evious evaluation
for impotence.

Online medical evaluations
do not meet reasonable
standards of care

Armstr ong and colleagues looked further at the content and design of the medical
history questionnaire. Taking a medical histor y before prescribing Viagra ® is essential
because of the medical risks to patients taking cer tain hear t medications (nitrates).
Taking nitrates and Viagra ® together could cause a serious fall in blood pressure.
• Only 27 sites (35%) specified that a physician would r eview the questionnaire,
and no site provided information about the physician’s qualifications or specialty.
• Of the 44 sites (60%) that included a questionnair e, only 34 (44%) required
information on the use of nitrates. Forty sites (52%) asked about a diagnosis of
angina or cor onar y hear t disease; 33 sites (43%) asked about symptoms of
coronary hear t disease.
• Sites based outside of the U.S. wer e less likely to ask medical information, or to
provide information about risks.
• Consumers wer e asked to release the companies fr om liability in 52 sites (68%)
and specifically to waiv e their need for a physical examination in 12 sites (16%).

Obtaining prescription drugs
online is more costly for
patients

Although many sites adver tise lower prices to consumers than otherwise available,
Bloom and colleagues found that this was not the case. On average, prices for
Viagra ® and Propecia ® were about 10% mor e expensive when they were obtained
fr om a local Web site than fr om a local pharmacy . Of course, consumers may be
willing to pay more for the convenience of an online pharmacy.
• Based on the same dose, the median price per pill for Viagra ® was $5.49 thr ough
the Internet, as compar ed to $4.50 in Philadelphia-ar ea pharmacies. The median
price per pill for P ropecia ® was $1.94 thr ough the Internet, compar ed with $1.83
in Philadelphia-ar ea pharmacies. S hipping costs averaged $18 among U.S.-based
Web sites.
• Physician consultations were also more expensive than in-person visits. Internet
physician consultations ranged from $20 to $70 (median price, $70). This fee is
16.7% higher than payment b y managed car e organizations and Medicar e for a
primar y car e visit in the Philadelphia ar ea ($60).
• A U.S. patient using a U.S.-based Web site to obtain a physician consultation and
a 30-day supply of Propecia ® would pay a 40% pr emium ($68 more) for this
service, not including shipping costs.

Web sites selling prescription
drugs pose regulatory
challenges

Even in cases of clearly illegal activity (such as selling pr escription drugs without a
prescription), regulating these Web sites is difficult and unchar ted. Regulator y
challenges include:
• the ease with which Internet sites can appear and disappear , changing names and
appearance.
• multiple jurisdictions. FDA regulates mar keting of drugs, but not prescribing
once a dr ug is approved. States traditionally hav e r egulated both the pr escribing
and dispensing of drugs. Several states, ho wever, have found it difficult to identify
and locate violators and to bring effectiv e enforcement actions because the seller,
prescriber, and pur chaser of a dr ug may reside in different states.
• foreign sites, over which U.S. authorities hav e limited jurisdiction. It is illegal to
ship undeclared drugs into the U.S., but Customs Ser vice and Postal Ser vice
personnel cannot inspect all incoming packages.

Regulatory and professional
agencies are taking action to
protect the public

The availability of dr ugs over the I nternet has attracted the attention of v arious
groups. Because the r egulation of Internet sites is so difficult, most groups are tr ying
to influence the medical pr ofessionals that prescribe or dispense medications.
• In June 1999, the American M edical Association (AMA) issued guidelines for
physicians on Internet pr escribing. They state that any health car e practitioner
who offers a pr escription to a patient based solely on an online questionnaire,
without ever having met the patient, has generally not met the appr opriate
medical standar d of car e.
• More than a doz en state licensing boards have taken action against physicians who
prescribe over the I nternet to patients not known to them. These actions have
ranged fr om fines to license suspensions.
• A number of state attorneys general hav e filed lawsuits against Web site owners for
violating state laws (for example, pr oviding drugs without a pharmacy license in
that state, or mailing dr ugs to minors).
• Pfizer, the manufactur er of Viagra ®, filed a complaint asking the F ederal Trade
Commission (FTC) to assert authority over Internet pr escribing of Viagra ®. The
company believes that Internet sale of the dr ug based on an online questionnaire
does not adequately convey the risks of the product. In general, the FT C can act
when an online pharmacy makes false or misleading claims about the pr oducts it
provides.

POLICY IMPLICATIONS

These studies document some of the dangers posed by Internet dr ug prescribing.
Clearly, policies are needed to protect the public’s health while allowing the benefits
of electr onic pharmacy commer ce to continue.
• Consumers need to be able to distinguish between sites with questionable practices and legitimate sites. Towar d that end, the National Association of Boar ds of
Pharmacy (NABP) has star ted a ne w program to verify the licensur e of Internet
pharmacy sites and inform the public about whether those sites ar e in good
standing with the appr opriate state boar d(s) of pharmacy. The program will
provide a NABP “ seal of appr oval” to sites meeting the organization’s standar ds.
Over time, this seal of appr oval may assur e consumers that the designated sites ar e
offering FDA-appr oved drugs and meet medical practice standar ds.

Continued on back.

POLICY IMPLICATIONS
Continued

• State licensing boar ds should move quickly to establish and enforce guidelines for
health pr ofessional involvement in Internet pr escribing. States should also
consider developing new regulations for Web-based pharmacy sites, if existing
regulations do not address the documented problems.
• The federal go vernment can support state enfor cement effor ts through interagency cooperation among the FDA, the FT C, and other r egulator y bodies. New
legislation may be necessary to ensure that Web site owners ar e traceable and
accountable. I n August, Rep. Ron Klink of Pennsylvania intr oduced the “Internet
Pharmacy Consumer Protection Act.” The bill would require Web-based pharmacies to list the name of principal practitioner , the addr ess and telephone number
of the principal place of business, and in what states the pharmacy and the
pharmacists ar e licensed to do business. tI would give the FDA the power to
enforce these provisions.
• Effectiv e strategies to addr ess non-U.S. sites will require cooperative effor ts of
customs authorities, the pharmaceutical industr y, and national and international
regulator y agencies.

This Issue Brief is based on the following two articles: K. Armstrong, J.S. Schwartz, D.A. Asch. Direct sale of Viagra to consumers over the Internet.
New England Journal of Medicine, October 28, 1999, vol. 341, pp. 1389-1392; B.S. Bloom, R.C. Iannacone. Internet availability of prescription pharmaceuticals to the public. Annals of Internal Medicine, vol. 141, Advance Web publication, September 1999.
Published by the Leonard Davis Institute of Health Economics, University of Pennsylvania, 3641 Locust Walk, Philadelphia, PA 19104-6218,
215-898-5611.
Janet Weiner, MPH, Associate Director for Health Policy, Editor
David A. Asch, MD, MBA, Executive Director

Visit us on the web at www.upenn.edu/ldi/

Issue Briefs synthesize the results of research by LDI’s Senior Fellows, a consortium of Penn scholars studying medical, economic, and social and
ethical issues that influence how health care is organized, financed, managed, and delivered in the United States and internationally. The LDI is a
cooperative venture among Penn schools including Dental Medicine, Medicine, Nursing and Wharton. For additional information on this or other
Issue Briefs, contact Janet Weiner (e-mail: weinerja@mail.med.upenn.edu; 215-573-9374).

Wishing you a happy and healthy holiday season!

ADDRESS CORRECTION REQUESTED

3641 Locust Walk
Philadelphia, PA 19104-6218
215.898.5611
fax 215.898.0229
Published by the
Leonard Davis Institute
of Health Economics
University of Pennsylvania

Issue Brief
P A I D
Permit No. 2563
Philadelphia, PA 19104
Nonprofit Organization
U.S. Postage

